Los Angeles-based Cedars-Sinai has deployed OpenEvidence systemwide, giving clinicians access to patient-specific medical literature within its EHR.
The clinical reference tool links peer-reviewed evidence to patient data — including prior procedures, medications, allergies and comorbidities — to support diagnosis and treatment decisions. Cedars-Sinai also plans to integrate its own care pathways and protocols into the platform, according to a May 20 news release.
The integration gives clinicians “a more complete and actionable understanding at the moment of care,” Cedars-Sinai Chief Health Informatics Officer Shaun Miller, MD, said in the release.
The deal follows a similar partnership announced March 31 between OpenEvidence and New York City-based Mount Sinai Health System, which the AI company described as its first enterprise deal with a health system.
OpenEvidence raised $250 million at a $12 billion valuation in January, up from $1 billion just over a year prior. The platform, which is free for physicians and trained solely on medical journals and data, says it was used by roughly 65% of U.S. physicians across nearly 27 million clinical encounters in April, according to NBC News.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
